SciSparc Ltd. (“Company” or “SciSparc”), announced that NeuroThera Labs Inc.  ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).

The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.

SCI-210 is an innovative proprietary combination of cannabidiol (“CBD”) and CannAmide™, NeuroThera’s Palmitoylethanolamide-based proprietary formulation. The treatment is being assessed for its ability to alleviate symptoms associated with ASD and to determine whether the dual‑compound approach offers advantages beyond CBD monotherapy.

The study is designed to evaluate the efficacy and safety of SCI-210 compared with CBD monotherapy. The trial’s primary efficacy endpoints include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) assessment conducted by a clinician, and determination of the optimal therapeutic dose.

The ongoing clinical trial is a key element of NeuroThera’s program for SCI-210 and reflects NeuroThera’s broader commitment to advancing innovative treatments for neurological and neurodevelopmental conditions. The study was designed in collaboration with the National Autism Research Center, a leading authority on autism research in Israel.

Subject to the successful completion of the clinical development program and receipt of applicable regulatory approvals, NeuroThera intends to pursue the commercialization of SCI-210, initially in Israel and subsequently in additional markets.